BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 37437874)

  • 1. Association between serum neurofilament light chain levels and sleep disorders in patients with Parkinson's disease.
    Li Y; Li F; Liu X; Zu J; Zhang W; Zhou S; Zhu J; Zhang T; Cui G; Xu C
    Neurosci Lett; 2023 Aug; 812():137394. PubMed ID: 37437874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relationship between serum neurofilament light chain and glial fibrillary acidic protein with the REM sleep behavior disorder subtype of Parkinson's disease.
    Teng X; Mao S; Wu H; Shao Q; Zu J; Zhang W; Zhou S; Zhang T; Zhu J; Cui G; Xu C
    J Neurochem; 2023 Apr; 165(2):268-276. PubMed ID: 36776136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of serum neurofilament light chain and glial fibrillary acidic protein levels with cognitive decline in Parkinson's disease.
    Mao S; Teng X; Li Z; Zu J; Zhang T; Xu C; Cui G
    Brain Res; 2023 Apr; 1805():148271. PubMed ID: 36754139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between increased serum neurofilament light chain and glial fibrillary acidic protein levels with non-motor symptoms in patients with Parkinson's disease.
    Yin P; Niu X; Guan C; Zhang Z; Liu Y; Li J; Cui G; Zan K; Xu C
    Psychogeriatrics; 2024 Mar; 24(2):415-425. PubMed ID: 38339819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of serum neurofilament light chain and glial fibrillary acidic protein as diagnostic biomarkers of freezing of gait in Parkinson's disease.
    Liu X; Liu X; Liu Y; Yang B; Li Y; Li F; Qian K; Zu J; Zhang W; Zhou S; Zhang T; Liu J; Cui G; Xu C
    Brain Res; 2024 Jan; 1822():148660. PubMed ID: 37924925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations of sleep disorders with serum neurofilament light chain levels in Parkinson's disease.
    Qi WY; Sun Y; Guo Y; Tan L
    BMC Neurol; 2024 May; 24(1):147. PubMed ID: 38693483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of plasma levels of NFL, GFAP, UCHL1 and tau as Parkinson's disease biomarkers using multiplexed single molecule counting.
    Youssef P; Hughes L; Kim WS; Halliday GM; Lewis SJG; Cooper A; Dzamko N
    Sci Rep; 2023 Mar; 13(1):5217. PubMed ID: 36997567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum glial fibrillary acidic protein and neurofilament light chain in treatment-naïve patients with unipolar depression.
    Hviid CVB; Benros ME; Krogh J; Nordentoft M; Christensen SH
    J Affect Disord; 2023 Oct; 338():341-348. PubMed ID: 37336248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of plasma Neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early Parkinson's disease.
    Ng ASL; Tan YJ; Yong ACW; Saffari SE; Lu Z; Ng EY; Ng SYE; Chia NSY; Choi X; Heng D; Neo S; Xu Z; Keong NCH; Tay KY; Au WL; Tan LCS; Tan EK
    Mol Neurodegener; 2020 Jun; 15(1):33. PubMed ID: 32503574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association of serum neurofilament light chains with early symptoms related to Parkinson's disease: A cross-sectional study.
    Wang X; Yang X; He W; Song X; Zhang G; Niu P; Chen T
    J Affect Disord; 2023 Dec; 343():144-152. PubMed ID: 37805158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma glial fibrillary acidic protein as a biomarker of disease progression in Parkinson's disease: a prospective cohort study.
    Lin J; Ou R; Li C; Hou Y; Zhang L; Wei Q; Pang D; Liu K; Jiang Q; Yang T; Xiao Y; Zhao B; Chen X; Song W; Yang J; Wu Y; Shang H
    BMC Med; 2023 Nov; 21(1):420. PubMed ID: 37932720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum Neurofilament Light Chain and Glial Fibrillary Acidic Protein as Potential Diagnostic Biomarkers in Autism Spectrum Disorders: A Preliminary Study.
    Simone M; De Giacomo A; Palumbi R; Palazzo C; Lucisano G; Pompamea F; Micella S; Pascali M; Gabellone A; Marzulli L; Giordano P; Gargano CD; Margari L; Frigeri A; Ruggieri M
    Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurofilament light predicts worse nonmotor symptoms and depression in Parkinson's disease.
    Urso D; Batzu L; Logroscino G; Ray Chaudhuri K; Pereira JB
    Neurobiol Dis; 2023 Sep; 185():106237. PubMed ID: 37499883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pediatric reference intervals for serum neurofilament light and glial fibrillary acidic protein using the Canadian Laboratory Initiative on Pediatric Reference Intervals (CALIPER) cohort.
    Stukas S; Cooper J; Higgins V; Holmes D; Adeli K; Wellington CL
    Clin Chem Lab Med; 2024 Mar; 62(4):698-705. PubMed ID: 37882772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma glial fibrillary acidic protein and neurofilament light chain in relation to disability worsening in multiple sclerosis.
    Pauwels A; Van Schependom J; Devolder L; Van Remoortel A; Nagels G; Bjerke M; D'hooghe MB
    Mult Scler; 2022 Oct; 28(11):1685-1696. PubMed ID: 36059263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intraindividual Neurofilament Dynamics in Serum Mark the Conversion to Sporadic Parkinson's Disease.
    Wilke C; Dos Santos MCT; Schulte C; Deuschle C; Scheller D; Verbelen M; Brockmann K; von Thaler AK; Sünkel U; Roeben B; Bujac S; Metzger FG; Maetzler W; da Costa AN; Synofzik M; Berg D
    Mov Disord; 2020 Jul; 35(7):1233-1238. PubMed ID: 32338403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma neurofilament light chain levels are associated with depressive and anxiety symptoms in Parkinson's disease.
    Yin W; Zhu Y; Yang B; Wang F; Yin K; Zhou C; Ren H; Yang X
    Neurol Sci; 2022 Apr; 43(4):2839-2843. PubMed ID: 35088243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum GFAP and NfL levels in benign relapsing-remitting multiple sclerosis.
    Niiranen M; Kontkanen A; Jääskeläinen O; Tertsunen HM; Selander T; Hartikainen P; Huber N; Solje E; Haapasalo A; Kokkola T; Lohioja T; Herukka SK; Simula S; Remes AM
    Mult Scler Relat Disord; 2021 Nov; 56():103280. PubMed ID: 34627002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum and cerebrospinal fluid brain damage markers neurofilament light and glial fibrillary acidic protein correlate with tick-borne encephalitis disease severity-a multicentre study on Lithuanian and Swedish patients.
    Veje M; Griška V; Pakalnienė J; Mickienė A; Bremell D; Zetterberg H; Blennow K; Lindquist L; Studahl M
    Eur J Neurol; 2023 Oct; 30(10):3182-3189. PubMed ID: 37431060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurofilament Light Chain and Glial Fibrillary Acidic Protein as early prognostic biomarkers after out-of-hospital cardiac arrest.
    Klitholm M; Jeppesen AN; Christensen S; Parkner T; Tybirk L; Kirkegaard H; Sandfeld-Paulsen B; Grejs AM
    Resuscitation; 2023 Dec; 193():109983. PubMed ID: 37778613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.